Cargando…

Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model

This study evaluates the costs and utilities of different treatment strategies for stable chronic obstructive pulmonary disease (COPD) patients based on Markov model and provides guidance for clinical decision and health policy making. Patients with stable COPD from four subcenters had been investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xue-qing, Yang, Shu-guang, Li, Han, Xie, Yang, Li, Jian-sheng, Zhang, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500607/
https://www.ncbi.nlm.nih.gov/pubmed/31118965
http://dx.doi.org/10.1155/2019/6478926
_version_ 1783415978938335232
author Yu, Xue-qing
Yang, Shu-guang
Li, Han
Xie, Yang
Li, Jian-sheng
Zhang, Pan
author_facet Yu, Xue-qing
Yang, Shu-guang
Li, Han
Xie, Yang
Li, Jian-sheng
Zhang, Pan
author_sort Yu, Xue-qing
collection PubMed
description This study evaluates the costs and utilities of different treatment strategies for stable chronic obstructive pulmonary disease (COPD) patients based on Markov model and provides guidance for clinical decision and health policy making. Patients with stable COPD from four subcenters had been investigated. A Markov model with three states, namely, GOLD 1-2, GOLD 3-4, and death, was built using TreeAge Pro 2011 software. Cost-utility ratio (CUR) and incremental cost-utility ratio (ICUR) from forty Markov circles were applied to measuring the economics evaluation of three different treatments. A total of 236 stable COPD patients were randomly assigned into three groups, Western medicine group (79 cases), traditional Chinese medicine (TCM) group (79 cases), and combined group (78 cases). The results of Markov cohort simulation showed that the accumulative quality-adjusted life years (QALYs) of the three above groups per 100 000 people in 40 years were 1 702 773, 1 616 797, and 1 709 668 years, respectively, and the accumulative costs were 13 582 138 466, 1 207 904 113, and 14 656 607 371 Yuan, respectively. The CURs of the three groups were 87 235, 74 602, and 87 223 Yuan/QALY, respectively. ICURs of combined group were 8 707 and 41 705 Yuan as against Western medicine group and TCM group, respectively. Therefore, combined treatment has a lower cost, higher health output, and more socioeconomic benefits in the long run. Markov model is recommended to conduct health economics evaluation of different treatments for COPD.
format Online
Article
Text
id pubmed-6500607
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65006072019-05-22 Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model Yu, Xue-qing Yang, Shu-guang Li, Han Xie, Yang Li, Jian-sheng Zhang, Pan Evid Based Complement Alternat Med Research Article This study evaluates the costs and utilities of different treatment strategies for stable chronic obstructive pulmonary disease (COPD) patients based on Markov model and provides guidance for clinical decision and health policy making. Patients with stable COPD from four subcenters had been investigated. A Markov model with three states, namely, GOLD 1-2, GOLD 3-4, and death, was built using TreeAge Pro 2011 software. Cost-utility ratio (CUR) and incremental cost-utility ratio (ICUR) from forty Markov circles were applied to measuring the economics evaluation of three different treatments. A total of 236 stable COPD patients were randomly assigned into three groups, Western medicine group (79 cases), traditional Chinese medicine (TCM) group (79 cases), and combined group (78 cases). The results of Markov cohort simulation showed that the accumulative quality-adjusted life years (QALYs) of the three above groups per 100 000 people in 40 years were 1 702 773, 1 616 797, and 1 709 668 years, respectively, and the accumulative costs were 13 582 138 466, 1 207 904 113, and 14 656 607 371 Yuan, respectively. The CURs of the three groups were 87 235, 74 602, and 87 223 Yuan/QALY, respectively. ICURs of combined group were 8 707 and 41 705 Yuan as against Western medicine group and TCM group, respectively. Therefore, combined treatment has a lower cost, higher health output, and more socioeconomic benefits in the long run. Markov model is recommended to conduct health economics evaluation of different treatments for COPD. Hindawi 2019-04-17 /pmc/articles/PMC6500607/ /pubmed/31118965 http://dx.doi.org/10.1155/2019/6478926 Text en Copyright © 2019 Xue-qing Yu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yu, Xue-qing
Yang, Shu-guang
Li, Han
Xie, Yang
Li, Jian-sheng
Zhang, Pan
Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model
title Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model
title_full Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model
title_fullStr Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model
title_full_unstemmed Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model
title_short Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model
title_sort preliminary study to evaluate three different treatments on stable chronic obstructive pulmonary disease patients based on markov model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500607/
https://www.ncbi.nlm.nih.gov/pubmed/31118965
http://dx.doi.org/10.1155/2019/6478926
work_keys_str_mv AT yuxueqing preliminarystudytoevaluatethreedifferenttreatmentsonstablechronicobstructivepulmonarydiseasepatientsbasedonmarkovmodel
AT yangshuguang preliminarystudytoevaluatethreedifferenttreatmentsonstablechronicobstructivepulmonarydiseasepatientsbasedonmarkovmodel
AT lihan preliminarystudytoevaluatethreedifferenttreatmentsonstablechronicobstructivepulmonarydiseasepatientsbasedonmarkovmodel
AT xieyang preliminarystudytoevaluatethreedifferenttreatmentsonstablechronicobstructivepulmonarydiseasepatientsbasedonmarkovmodel
AT lijiansheng preliminarystudytoevaluatethreedifferenttreatmentsonstablechronicobstructivepulmonarydiseasepatientsbasedonmarkovmodel
AT zhangpan preliminarystudytoevaluatethreedifferenttreatmentsonstablechronicobstructivepulmonarydiseasepatientsbasedonmarkovmodel